HUP0302991A2 - Izoxazolok és alkalmazásuk ERK inhibitorokként és a vegyületeket tartalmazó gyógyszerkészítmények - Google Patents
Izoxazolok és alkalmazásuk ERK inhibitorokként és a vegyületeket tartalmazó gyógyszerkészítményekInfo
- Publication number
- HUP0302991A2 HUP0302991A2 HU0302991A HUP0302991A HUP0302991A2 HU P0302991 A2 HUP0302991 A2 HU P0302991A2 HU 0302991 A HU0302991 A HU 0302991A HU P0302991 A HUP0302991 A HU P0302991A HU P0302991 A2 HUP0302991 A2 HU P0302991A2
- Authority
- HU
- Hungary
- Prior art keywords
- group
- aralkyl
- carbon atoms
- aliphatic group
- heterocyclyl
- Prior art date
Links
- 150000002545 isoxazoles Chemical class 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000001931 aliphatic group Chemical group 0.000 abstract 4
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 4
- 125000004432 carbon atom Chemical group C* 0.000 abstract 4
- -1 pyrrol-3-yl- Chemical group 0.000 abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 229910052731 fluorine Inorganic materials 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 239000011737 fluorine Chemical group 0.000 abstract 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 125000002015 acyclic group Chemical group 0.000 abstract 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000005160 aryl oxy alkyl group Chemical group 0.000 abstract 1
- 230000008878 coupling Effects 0.000 abstract 1
- 238000010168 coupling process Methods 0.000 abstract 1
- 238000005859 coupling reaction Methods 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000004475 heteroaralkyl group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
- 125000004289 pyrazol-3-yl group Chemical group [H]N1N=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 125000004299 tetrazol-5-yl group Chemical group [H]N1N=NC(*)=N1 0.000 abstract 1
- 125000001425 triazolyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
Abstract
A találmány tárgyát az általános képletű, protein-kináz inhibitorhatású izoxazolok - ahol Ht pirrol-3-il-, pirazol-3-il-,[1,2,4]triazol-3-il-,[1,2,3]triazol-4-il-, vagy tetrazol-5-il-csoport;ahol a pirrol-3-il- és pirazol-3-il-csoport mindegyike R3 és QR4szubsztituenseket tartalmaz, és az említett triazol R3 vagy QR4csoporttal szubsztituált; A-B -N-O vagy -O-N; R1 R5, fluoratom, -N(R5)2, -OR, -NRCOR, -CON(R5)2, -SO2R, -NRSO2R vagy -SO2N(R5)2 ; T ésQ vegyértékkötés vagy kapcsolócsoport; R mindegyike egymástólfüggetlenül hidrogénatom vagy adott esetben szubsztituált, 1-6szénatomos alifás csoport; R2 hidrogénatom, -CN, fluor vagy adottesetben szubsztituált aril-, heteroaril-, heterociklil-, 1-6szénatomos aciklusos alifás csoport vagy 4-10 szénatomos ciklusosalifás csoport; L C1-C6-alkilidén-lánc, ahol L két metilén egységét -C(O)-, -C(O)C(O)-, -CONH-, -CONHNH-, -CO2-, -OC(O)-, -NHCO2-, -O-, -NHCONH-, -OC(O)NH-, -NHNH-, -NHCO-, -S-, -SO-, -SO2-, -NH-, -SO2NH-, -NHSO2NH- vagy -NHSO2- csoport helyettesíti; W R9, -CH(R9)2, -CH(R9)N(R9)2 vagy -N(R9)2 R3 R, -OH, -OR, -N(R)2, fluoratom vagy -CNcsoport; R4 -R6, -NH2, -NHR6, -N(R6)2 vagy -NR6(CH2)yN(R6)2 R5mindegyike hidrogén vagy 1-6 szénatomos alifás csoport vagy anitrogénen elhelyezkedő két R5 a nitrogénnel 1-3 heteroatomottartalmazó 4-8 tagú gyűrűt képezhet; R6 mindegyike R5, (CH2)yCH(R7)2vagy -(CH2)yR7 ; Y = 0-6; R7 mindegyike adott esetben szubsztituált R,aril-, aralkil-, aralkoxi-, heteroaril-, heteroaril-alkil-,heteroaril-alkoxi-, heterociklil-, heterociklil-alkil-, heterociklil-alkoxi-, hidroxi-alkil-, alkoxi-alkil-, aril-oxi-alkil vagy alkoxi-karbonil-csoport; R8 mindegyike halogén, -R', -OR', -SR', -NO2, -CN, -N(R5)2. -NRC(O)R', -NRC(O)N(R5)2, -NRCO2R', -NRNRC(O)R', -NRNRC(O)N(R5)2, -NRNRCO2R', -C(O)C(O)R', -C(O)CH2C(O)R', -CO2R', -C(O)R', -C(O)N(R5)2, -OC(O)N(R5)2, -S(O)2R', -SO2N(R5)2, -S(O)R', -NRSO2N(R5)2, -NRSO2R', -C(=S)N(R5)2 vagy -C(=NH)N(R5)2 általánosképletű csoport és R9 mindegyike R5, R8 vagy aril-, aralkil-,aralkoxi-, heteroaril-, heteroaralkil-, heterociklil- vagyheterociklil-alkilcsoport - és alkalmazásaik képezik. Ó
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23295600P | 2000-09-15 | 2000-09-15 | |
PCT/US2001/028790 WO2002022610A1 (en) | 2000-09-15 | 2001-09-14 | Isoxazoles and their use as inhibitors of erk |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0302991A2 true HUP0302991A2 (hu) | 2003-12-29 |
HUP0302991A3 HUP0302991A3 (en) | 2009-10-28 |
Family
ID=22875248
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0302991A HUP0302991A3 (en) | 2000-09-15 | 2001-09-14 | Isoxazoles and their use as inhibitors of erk and pharmaceutical compositions containing the compounds |
Country Status (16)
Country | Link |
---|---|
US (3) | US6495582B1 (hu) |
EP (1) | EP1317453B1 (hu) |
JP (1) | JP4052573B2 (hu) |
AT (1) | ATE335737T1 (hu) |
AU (1) | AU2001290940A1 (hu) |
CA (1) | CA2422376A1 (hu) |
DE (1) | DE60122176T2 (hu) |
ES (1) | ES2269458T3 (hu) |
HK (1) | HK1052934B (hu) |
HU (1) | HUP0302991A3 (hu) |
IL (1) | IL154710A0 (hu) |
MX (1) | MXPA03002296A (hu) |
NO (1) | NO325089B1 (hu) |
NZ (1) | NZ525016A (hu) |
WO (1) | WO2002022610A1 (hu) |
ZA (1) | ZA200301696B (hu) |
Families Citing this family (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU5467699A (en) * | 1998-08-07 | 2000-02-28 | Chiron Corporation | Substituted isoxazole as estrogen receptor modulators |
US20020142982A1 (en) * | 1999-09-02 | 2002-10-03 | Timothy Hla | Method for regulating angiogenesis |
WO2002014271A1 (fr) * | 2000-08-10 | 2002-02-21 | Mitsubishi Pharma Corporation | Dérivés de proline et leur utilisation comme médicaments |
US6660731B2 (en) * | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
WO2002022605A1 (en) * | 2000-09-15 | 2002-03-21 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US7473691B2 (en) * | 2000-09-15 | 2009-01-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6989385B2 (en) * | 2000-12-21 | 2006-01-24 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6589997B2 (en) * | 2001-06-29 | 2003-07-08 | North Shore-Long Island Jewish Health System | Small-molecule modulators of hepatocyte growth factor/scatter factor activities |
JP4342939B2 (ja) | 2001-08-03 | 2009-10-14 | バーテックス ファーマシューティカルズ インコーポレイテッド | ピラゾール誘導キナーゼインヒビターおよびその使用 |
NZ530782A (en) * | 2001-08-06 | 2005-11-25 | Pharmacia Italia S | Aminoisoxazole derivatives active as kinase inhibitors |
RU2004126671A (ru) * | 2002-02-06 | 2005-04-10 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Гетероарилсоединения, полезные в качестве ингибиторов gsk-3 |
US20040009981A1 (en) * | 2002-03-15 | 2004-01-15 | David Bebbington | Compositions useful as inhibitors of protein kinases |
MY141867A (en) * | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
WO2004000318A2 (en) | 2002-06-21 | 2003-12-31 | Cellular Genomics, Inc. | Certain amino-substituted monocycles as kinase modulators |
EA200500299A1 (ru) | 2002-08-02 | 2005-08-25 | Вертекс Фармасьютикалз Инкорпорейтед | Пиразольные композиции, используемые в качестве ингибиторов gsk-3 |
US7196078B2 (en) | 2002-09-04 | 2007-03-27 | Schering Corpoartion | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors |
US7119200B2 (en) | 2002-09-04 | 2006-10-10 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
EP2194058B1 (en) | 2002-09-04 | 2013-11-27 | Merck Sharp & Dohme Corp. | Pyrazolopyrimidines suitable for the treatment of cancer diseases |
US8580782B2 (en) | 2002-09-04 | 2013-11-12 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
US7605155B2 (en) | 2002-09-04 | 2009-10-20 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
MXPA05002571A (es) | 2002-09-04 | 2005-09-08 | Schering Corp | Pirazolopirimidinas como inhibidores de cinasa dependientes de ciclina. |
US8673924B2 (en) | 2002-09-04 | 2014-03-18 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
WO2004072029A2 (en) * | 2003-02-06 | 2004-08-26 | Vertex Pharmaceuticals Incorporated | Pyrazolopyridazines useful as inhibitors of protein kinases |
DE602004012578T2 (de) * | 2003-08-15 | 2008-12-11 | Vertex Pharmaceuticals Inc., Cambridge | Als inhibitoren von c-met geeignete pyrrolzusammensetzungen |
CN1902193B (zh) * | 2003-12-04 | 2011-07-13 | 沃泰克斯药物股份有限公司 | 可用作蛋白激酶抑制剂的喹喔啉 |
WO2006011136A2 (en) * | 2004-07-26 | 2006-02-02 | Ben Gurion University Of The Negev Research And Development Authority | Novel naphthoquinone derivatives and uses thereof |
US7429667B2 (en) | 2005-01-20 | 2008-09-30 | Ardea Biosciences, Inc. | Phenylamino isothiazole carboxamidines as MEK inhibitors |
SG164378A1 (en) | 2005-02-17 | 2010-09-29 | Synta Pharmaceuticals Corp | Compounds for the treatment of proliferative disorders |
WO2007022384A2 (en) * | 2005-08-18 | 2007-02-22 | Vertex Pharmaceuticals Incorporated | Pyrazine kinase inhibitors |
DE602006003777D1 (de) | 2005-09-19 | 2009-01-02 | Hoffmann La Roche | Isoxazolderivate als inverse gaba a alpha5 agonisten |
AR056206A1 (es) | 2005-10-06 | 2007-09-26 | Schering Corp | Pirazolpirimidinas como inhibidores de protein quinasas |
CN101316847A (zh) | 2005-10-06 | 2008-12-03 | 先灵公司 | 用作蛋白激酶抑制剂的吡唑并(1,5a)嘧啶化合物 |
NZ594383A (en) * | 2005-11-03 | 2013-05-31 | Vertex Pharma | Aminopyrimidines useful as kinase inhibitors |
KR20080074963A (ko) | 2005-11-10 | 2008-08-13 | 쉐링 코포레이션 | 단백질 키나제 억제제로서의 이미다조피라진 |
US8546404B2 (en) | 2005-12-13 | 2013-10-01 | Merck Sharp & Dohme | Compounds that are ERK inhibitors |
KR101394245B1 (ko) * | 2005-12-30 | 2014-05-14 | 에스케이바이오팜 주식회사 | 아이속사졸 유도체 및 이의 용도 |
KR20080103996A (ko) | 2006-02-16 | 2008-11-28 | 쉐링 코포레이션 | Erk 억제제로서 피롤리딘 유도체 |
US7842836B2 (en) | 2006-04-11 | 2010-11-30 | Ardea Biosciences | N-aryl-N'alkyl sulfamides as MEK inhibitors |
CA2649122C (en) * | 2006-04-18 | 2015-06-30 | Ardea Biosciences, Inc. | Pyridone sulfonamides and pyridone sulfamides as mek inhibitors |
US20090175852A1 (en) | 2006-06-06 | 2009-07-09 | Schering Corporation | Imidazopyrazines as protein kinase inhibitors |
WO2008054702A1 (en) | 2006-10-31 | 2008-05-08 | Schering Corporation | Anilinopiperazine derivatives and methods of use thereof |
JP5103604B2 (ja) | 2006-10-31 | 2012-12-19 | メルク・シャープ・アンド・ドーム・コーポレーション | プロテインキナーゼ阻害剤としての2−アミノチアゾール−4−カルボン酸アミド |
MX2009004791A (es) | 2006-10-31 | 2009-08-19 | Schering Corp | Derivados de anilinopiperazina t metodos de uso de los mismos. |
NZ576750A (en) * | 2006-11-02 | 2012-01-12 | Vertex Pharma | Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases |
EP2099787B1 (en) * | 2006-12-19 | 2010-07-21 | Vertex Pharmaceuticals, Inc. | Aminopyrimidines useful as inhibitors of protein kinases |
CN101663295B (zh) * | 2007-03-09 | 2014-11-05 | 沃泰克斯药物股份有限公司 | 可用作蛋白激酶抑制剂的氨基嘧啶类化合物 |
NZ579483A (en) | 2007-03-09 | 2012-07-27 | Vertex Pharma | Aminopyridines useful as inhibitors of protein kinases |
RU2009137390A (ru) * | 2007-03-09 | 2011-04-20 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Аминопиримидины, пригодные в качестве ингибиторов протеинкиназ |
MX2009011059A (es) | 2007-04-13 | 2009-11-26 | Vertex Pharma | Aminopirimidinas utiles como inhibidores de cinasas. |
US8509487B2 (en) * | 2007-04-19 | 2013-08-13 | Avago Technologies General Ip (Singapore) Pte. Ltd. | System and method for optically measuring a parameter of an object |
AU2008247594A1 (en) * | 2007-05-02 | 2008-11-13 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
JP5389785B2 (ja) * | 2007-05-02 | 2014-01-15 | バーテックス ファーマシューティカルズ インコーポレイテッド | キナーゼ阻害剤として有用なチアゾールおよびピラゾール |
MX2009011811A (es) * | 2007-05-02 | 2010-01-14 | Vertex Pharma | Aminopirimidinas utiles como inhibidores de cinasa. |
JP2010528021A (ja) * | 2007-05-24 | 2010-08-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | キナーゼのインヒビターとして有用なチアゾールおよびピラゾール |
EP2178861B1 (en) | 2007-07-19 | 2014-08-20 | Merck Sharp & Dohme Corp. | Heterocyclic amide compounds as protein kinase inhibitors |
NZ582879A (en) * | 2007-07-31 | 2012-03-30 | Vertex Pharma | Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof |
AU2008293542B9 (en) | 2007-08-27 | 2014-08-07 | Dart Neuroscience (Cayman) Ltd. | Therapeutic isoxazole compounds |
WO2009058728A1 (en) | 2007-10-29 | 2009-05-07 | Schering Corporation | Thiazole derivatives as protein kinase inhibitors |
MY152271A (en) | 2008-02-21 | 2014-09-15 | Merck Sharp & Dohme | Novel compounds that are erk inhibitors |
US20110160256A1 (en) * | 2008-06-26 | 2011-06-30 | Rouse Meagan B | Inhibitors of akt activity |
KR20110050549A (ko) * | 2008-09-03 | 2011-05-13 | 버텍스 파마슈티칼스 인코포레이티드 | 공-결정 및 이를 포함하는 제약 제제 |
EP2470183B1 (en) | 2009-08-26 | 2015-09-16 | Merck Sharp & Dohme Corp. | Heterocyclic amide compounds as protein kinase inhibitors |
AU2011285611B2 (en) | 2010-08-05 | 2014-10-02 | Case Western Reserve University | Inhibitors of ERK for developmental disorders of neuronal connectivity |
WO2013109142A1 (en) | 2012-01-16 | 2013-07-25 | Stichting Het Nederlands Kanker Instituut | Combined pdk and mapk/erk pathway inhibition in neoplasia |
HUE051096T2 (hu) | 2012-04-26 | 2021-03-01 | Massachusetts Gen Hospital | Ágensek és módszerek a sebészeti keratózis kezelésére és megelõzésére |
ES2661394T3 (es) * | 2012-07-16 | 2018-03-28 | Neuropore Therapies, Inc. | Derivados de di- y tri-heteroarilo como inhibidores de la agregación de proteínas |
WO2014186663A2 (en) * | 2013-05-17 | 2014-11-20 | The General Hospital Corporation | Methods for detecting and treating variants of seborrheic keratoses |
EP3024457A4 (en) | 2013-07-26 | 2017-06-28 | Update Pharma Inc. | Compositions to improve the therapeutic benefit of bisantrene |
WO2015041533A1 (en) | 2013-09-20 | 2015-03-26 | Stichting Het Nederlands Kanker Instituut | Rock in combination with mapk-pathway |
WO2015041534A1 (en) | 2013-09-20 | 2015-03-26 | Stichting Het Nederlands Kanker Instituut | P90rsk in combination with raf/erk/mek |
US20170027940A1 (en) | 2014-04-10 | 2017-02-02 | Stichting Het Nederlands Kanker Instituut | Method for treating cancer |
WO2015178770A1 (en) | 2014-05-19 | 2015-11-26 | Stichting Het Nederlands Kanker Instituut | Compositions for cancer treatment |
AU2015328411C1 (en) | 2014-10-06 | 2022-03-03 | Dana-Farber Cancer Institute, Inc. | Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response |
MA41866A (fr) | 2015-03-31 | 2018-02-06 | Massachusetts Gen Hospital | Molécules à auto-assemblage pour l'administration ciblée de médicaments |
EP3355923B1 (en) | 2015-10-01 | 2022-02-23 | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis | Histone deacetylase inhibitors for use in the treatment of drug resistant melanoma |
WO2017099591A1 (en) | 2015-12-07 | 2017-06-15 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Treatment of inhibitor resistant braf-mutant cancers |
WO2017204626A1 (en) | 2016-05-24 | 2017-11-30 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Combination therapy - combined map2k4/map3k1 and mek/erk inhibition |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5498720A (en) | 1993-08-26 | 1996-03-12 | Lee; An-Rong | Certain triazole compounds and their pharmaceutical uses |
DE4438824A1 (de) * | 1993-10-16 | 1995-04-20 | Schering Ag | Triazolderivate, Verfahren zu deren Herstellung und deren Verwendung in Arzneimitteln |
JP3542827B2 (ja) * | 1994-07-15 | 2004-07-14 | 帝国臓器製薬株式会社 | 新規な5−置換イソキサゾール−3−カルボン酸アミド誘導体 |
US5470862A (en) * | 1995-02-03 | 1995-11-28 | Ohmeda Pharmaceutical Products Division Inc. | Substituted pyrazolyl compounds and methods employing such compounds |
UA52698C2 (uk) * | 1996-10-04 | 2003-01-15 | Х. Луннбек А/С | Похідні (3-алкоксіізоксазол-4-іл)заміщеної 2-амінокарбонової кислоти та їх сірковмісні аналоги, фармацевтична композиція на їх основі |
EP0927166A1 (en) * | 1997-02-14 | 1999-07-07 | Bayer Corporation | Amides as npy5 receptor antagonists |
JP2002516325A (ja) * | 1998-05-26 | 2002-06-04 | スミスクライン・ビーチャム・コーポレイション | 新規な置換イミダゾール化合物 |
JP4191825B2 (ja) * | 1998-09-10 | 2008-12-03 | あすか製薬株式会社 | 5−アミノイソキサゾール誘導体 |
BR0104424A (pt) * | 2000-02-05 | 2002-01-08 | Vertex Pharma | Composições de pirazol úteis como inibidores de erk |
WO2001056557A2 (en) | 2000-02-05 | 2001-08-09 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of erk |
DE602004012578T2 (de) * | 2003-08-15 | 2008-12-11 | Vertex Pharmaceuticals Inc., Cambridge | Als inhibitoren von c-met geeignete pyrrolzusammensetzungen |
-
2001
- 2001-09-14 DE DE60122176T patent/DE60122176T2/de not_active Expired - Lifetime
- 2001-09-14 HU HU0302991A patent/HUP0302991A3/hu unknown
- 2001-09-14 CA CA002422376A patent/CA2422376A1/en not_active Abandoned
- 2001-09-14 AT AT01971002T patent/ATE335737T1/de not_active IP Right Cessation
- 2001-09-14 WO PCT/US2001/028790 patent/WO2002022610A1/en active IP Right Grant
- 2001-09-14 ZA ZA200301696A patent/ZA200301696B/en unknown
- 2001-09-14 JP JP2002526863A patent/JP4052573B2/ja not_active Expired - Fee Related
- 2001-09-14 NZ NZ525016A patent/NZ525016A/en unknown
- 2001-09-14 EP EP01971002A patent/EP1317453B1/en not_active Expired - Lifetime
- 2001-09-14 MX MXPA03002296A patent/MXPA03002296A/es not_active Application Discontinuation
- 2001-09-14 US US09/953,120 patent/US6495582B1/en not_active Expired - Lifetime
- 2001-09-14 IL IL15471001A patent/IL154710A0/xx unknown
- 2001-09-14 AU AU2001290940A patent/AU2001290940A1/en not_active Abandoned
- 2001-09-14 ES ES01971002T patent/ES2269458T3/es not_active Expired - Lifetime
-
2002
- 2002-10-15 US US10/272,622 patent/US6649640B2/en not_active Expired - Fee Related
-
2003
- 2003-03-14 NO NO20031192A patent/NO325089B1/no not_active IP Right Cessation
- 2003-07-16 HK HK03105158.4A patent/HK1052934B/zh not_active IP Right Cessation
- 2003-07-24 US US10/626,356 patent/US7354919B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP1317453A1 (en) | 2003-06-11 |
HUP0302991A3 (en) | 2009-10-28 |
HK1052934A1 (en) | 2003-10-03 |
MXPA03002296A (es) | 2003-06-06 |
ATE335737T1 (de) | 2006-09-15 |
US7354919B2 (en) | 2008-04-08 |
ES2269458T3 (es) | 2007-04-01 |
NO20031192D0 (no) | 2003-03-14 |
WO2002022610A1 (en) | 2002-03-21 |
ZA200301696B (en) | 2004-04-28 |
HK1052934B (zh) | 2007-01-12 |
NO325089B1 (no) | 2008-01-28 |
CA2422376A1 (en) | 2002-03-21 |
DE60122176T2 (de) | 2007-07-05 |
JP4052573B2 (ja) | 2008-02-27 |
DE60122176D1 (de) | 2006-09-21 |
US20050090536A1 (en) | 2005-04-28 |
NZ525016A (en) | 2004-10-29 |
AU2001290940A1 (en) | 2002-03-26 |
US6495582B1 (en) | 2002-12-17 |
US6649640B2 (en) | 2003-11-18 |
US20030195241A1 (en) | 2003-10-16 |
NO20031192L (no) | 2003-05-13 |
US20020177618A1 (en) | 2002-11-28 |
IL154710A0 (en) | 2003-10-31 |
JP2004509119A (ja) | 2004-03-25 |
EP1317453B1 (en) | 2006-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0302991A2 (hu) | Izoxazolok és alkalmazásuk ERK inhibitorokként és a vegyületeket tartalmazó gyógyszerkészítmények | |
MX2021015605A (es) | Compuestos 2,3-dihidroquinazolin como inhibidores nav1.8. | |
HUP0301236A2 (hu) | Szubsztituált kinazolinszármazékok és felhasználásuk inhibitorokként | |
WO2003024967A3 (en) | Indolizines as kinase protein inhibitors | |
HUP0300527A2 (hu) | Pirrolopirimidinon-származékok, a vegyületek előállítása és alkalmazása | |
HUP0001446A2 (hu) | HIV reverz transzkriptáz inhibitor hatású 4,4-diszubsztituált-3,4-dihidro-2(1H)-kinazolinon-származékok, alkalmazásuk és a vegyületeket tartalmazó gyógyszerkészítmények | |
HUP0100950A2 (hu) | Ciklusos aminovegyületek, alkalmazásuk gyógyászati készítmények előállítására és a vegyületeket tartalmazó gyógyászati készítmények | |
CA2545427A1 (en) | Selective kinase inhibitors | |
HUP0400828A2 (hu) | Kondenzált heterociklikus aminopirimidinek, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények | |
HUP0302893A2 (hu) | Nem-imidazol ariloxipiperidinek és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
HUP0204410A2 (en) | Pyrimidine-4-one derivatives, process for their preparation, pharmaceutical compositions containing them and their use | |
AP1541A (en) | New thiadazoles and oxadiazoles and their use as phosphodiesterase - 7 inhibitors. | |
ATE390421T1 (de) | Aminoheterocyclen als vr-1 antagonisten zur behandlung von schmerzen | |
HUP0102723A2 (hu) | Új difenilkarbamid-származékok, eljárás előállításukra és ezeket tartalmazó gyógyászati készítmények | |
CA2559128A1 (en) | Kinase inhibitors | |
HUP9901613A2 (hu) | Szubsztituált tetraciklusos kondenzált furán-amin-származékok, eljárás előállításukra, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények | |
FI964463A (fi) | Bisykliset amidiinijohdannaiset typpioksidinsyntetaasin inhibiittoreina | |
AP9901578A0 (en) | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents. | |
MY129312A (en) | Carbamate compounds for use in the treatment of pain | |
MXPA02012470A (es) | Inhibidores de fosfodiesterasa especificos para gmp ciclico. | |
MY140653A (en) | Substituted diketopiperazines and their use as oxytocyn antagonists | |
HUP0402515A2 (hu) | Szubsztituált új N-[4-(1H-imidazol-1-il)-2-fluor-fenil]-3-(trifluor-metil)-1H-pirazol-5-karboxamidok Xa faktor inhibitorok, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények | |
MXPA04005484A (es) | Procedimiento de preparacion de derivados de equinocandina. | |
HUP0302753A2 (hu) | Integrin inhibitor hatású karbamid- és uretánszármazékok, eljárás az előállításukra, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények | |
TR199900096T2 (xx) | Bradykinin B2 antagonistleri olarak elveri�li N-benzensulfonil-L-prolin t�revleri. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |